Kairos Pharma, LTD. (KAPA) stock
KAPANYSEPharmaceutical PreparationsFiscal year ends December 31
$0.44+0.04 (+10.08%)
Close on Nov 18, 2026Market cap $1.64MP/E –Yield –
Kairos Pharma operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Kairos Pharma's operating income for the twelve months ending Sep 30, 2026 was -$6.53M. For fiscal 2025 it was -$5.57M.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$5.57M | – |
| FY2024 | Dec 31, 2024 | -$2.34M | – |
| FY2023 | Dec 31, 2023 | -$1.71M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$2.01M | – |
| Q2 FY2026 | Jun 30, 2026 | -$1.42M | – |
| Q1 FY2026 | Mar 31, 2026 | -$1.69M | – |
| Q4 FY2025 | Dec 31, 2025 | -$1.42M | – |
| Q3 FY2025 | Sep 30, 2025 | -$1.44M | – |
| Q2 FY2025 | Jun 30, 2025 | -$1.46M | – |
| Q1 FY2025 | Mar 31, 2025 | -$1.27M | – |
| Q4 FY2024 | Dec 31, 2024 | -$1.45M | – |
| Q3 FY2024 | Sep 30, 2024 | -$383.00K | – |
| Q2 FY2024 | Jun 30, 2024 | -$222.00K | – |
| Q1 FY2024 | Mar 31, 2024 | -$287.00K | – |
| Q4 FY2023 | Dec 31, 2023 | -$1.09M | – |
| Q3 FY2023 | Sep 30, 2023 | -$287.00K | – |
See a number that looks wrong?